Help

HPV33 E6 Polyclonal Antibody, RBITC Conjugated

Applications

  • WB
  • IF(IHC-P)
  • IF(IHC-F)
  • IF(ICC)

Reactivity

  • Virus
Overview
Catalog # bs-2968R-RBITC-100uL
Product Name HPV33 E6 Polyclonal Antibody, RBITC Conjugated
Applications
WB IF(IHC-P) IF(IHC-F) IF(ICC)
Specificity This antibody will detect E6 in HPV33, HPV58, and Alphapapillomavirus 9.
Reactivity Virus
Specifications
Conjugation RBITC
Host Rabbit
Source KLH conjugated synthetic peptide derived from human HPV33 E6 protein
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Target
Synonyms E6 protein [Human papillomavirus type 33]; Human Papilloma Virus; Human papillomavirus type 33; Human papillomavirus type 33; Protein 33; HPV33-E6 protein; HPV33 E6 protein; VE6_HPV33.
Background Human papilloma viruses (HPVs) can be classified as either high risk or low risk according to their association with cancer. HPV16 and HPV18 are the most common of the high risk group while HPV6 and HPV11 are among the low risk types. Approximately 90% of cervical cancers contain HPV DNA of the high risk types. Mutational analysis have shown that the E6 and E7 genes of the high risk HPVs are necessary and sufficient for HPV transforming function. The specific interactions of the E6 and E7 proteins with p53 and pRB, respectively, correlate with HPV high and low risk classifications. The high risk HPV E7 proteins bind to pRB with a higher affinity than do the low risk HPV proteins, and only the high risk HPV E6 proteins form detectable complexes with p53 in vitro. Human papillomaviruses (HPV) are small DNA viruses which infect epithelia of the skin and mucosa. Over 90 types have been identified and they mostly cause a variety of benign lesions such as warts and verrucae. However, some subtypes, notably types 16 and 18, 31 and 33, have been confirmed as agents which cause cervical cancer. The E6 protein is a transcriptional transactivator. Binds double-stranded DNA. This protein may be involved in the oncogenic potential of this virus (cervical neoplasia-associated virus).
Application Dilution
WB 1:300-5000
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Frequently asked questions

Which applications is HPV33 E6 Polyclonal Antibody, RBITC Conjugated (bs-2968R-RBITC) validated for, and at what dilution?

bs-2968R-RBITC is validated for WB (1:300-5000); IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.

Which species does HPV33 E6 Polyclonal Antibody, RBITC Conjugated (bs-2968R-RBITC) react with?

Tested reactivity: Virus.

How should bs-2968R-RBITC be stored?

Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

What immunogen was used to raise HPV33 E6 Polyclonal Antibody, RBITC Conjugated (bs-2968R-RBITC)?

KLH conjugated synthetic peptide derived from human HPV33 E6 protein

What are the excitation and emission wavelengths of the RBITC conjugate (bs-2968R-RBITC)?

RBITC on bs-2968R-RBITC: excitation / emission 540nm/625nm.

Free sample offer

Try a recombinant sample

20 µL sample

Freewith your paid order

View product details (opens in a new tab)

View cart

US only. One sample per paid order, subject to review. Backorders may ship separately. Confirm Free at checkout. Check application and species suitability; same target does not guarantee equivalent performance. For research use only.

Primary antibody added to your cart

Need a secondary antibody?

Product validation image

Confirm application and cross-reactivity before use. Prices shown are before eligible cart discounts. Shipping and tax are calculated at checkout.

View cart